<?xml version="1.0" encoding="UTF-8"?>
<fig fig-type="Figure" xml:lang="en" specific-use="collapsible" id="embj2020106057-fig-0001ev" orientation="portrait" position="float">
 <label>Figure EV1</label>
 <caption>
  <title>(Related to Fig 
   <xref rid="embj2020106057-fig-0001" ref-type="fig">1</xref>). 
   <italic>
    <styled-content style="fixed-case" toggle="no">CH</styled-content>25H
   </italic> induction in 
   <styled-content style="fixed-case" toggle="no">COVID</styled-content>‐19‐infected patient and characterization of 
   <styled-content style="fixed-case" toggle="no">SARS</styled-content>‐CoV‐2 pseudovirus
  </title>
  <p>
   <list list-type="alpha-upper" id="embj2020106057-list-0007">
    <list-item>
     <p>The box plot shows the expression of 
      <italic>CH25H</italic> in epithelia of bronchoalveolar lavage fluids from four healthy donors, three moderate COVID‐19-infected patients and six severe COVID‐19-infected patients by scRNA‐seq analysis (Liao 
      <italic>et al</italic>, 
      <xref rid="embj2020106057-bib-0018" ref-type="ref">2020</xref>). *
      <italic>P</italic> &lt; 0.05, **
      <italic>P</italic> &lt; 0.01, by Student's 
      <italic>t</italic>‐test
     </p>
    </list-item>
    <list-item>
     <p>RNA‐seq analysis showed robust induction of 
      <italic>CH25H</italic> in PBMCs from COVID‐19-infected patients relative to healthy donors (Blanco‐Melo 
      <italic>et al</italic>, 
      <xref rid="embj2020106057-bib-0003" ref-type="ref">2020</xref>).
     </p>
    </list-item>
    <list-item>
     <p>Overexpression of SARS‐CoV-2 and SARS‐CoV spike protein in 293FT cells. The plasmids encoding SARS‐CoV-2 or SARS‐CoV spike protein was transfected in 293FT cells and expression of spike protein was analyzed by Western blotting using an antibody recognizing S2 subunit of SARS‐CoV and SARS‐CoV-2. Black arrows indicate full length spike protein and cleaved spike (S2 subunit), respectively.</p>
    </list-item>
    <list-item>
     <p>TMPRSS2 inhibitors, camostat and nafamostat, blocked entry of SARS‐CoV-2 but not VSV. Calu‐3 cells were treated with 10 μM camostat, 10 μM nafamostat or DMSO for 1 h. Then, the cells were infected with SARS‐CoV-2 or VSV pseudovirus with EGFP for 1 h. EGFP signals were captured by fluorescence microscope 24 h post‐infection. Scale bar, 100 μM.</p>
    </list-item>
    <list-item>
     <p>Knockout efficiency of ACE2 in Calu‐3 cells. Calu‐3 cells were transduced with non‐targeting control or ACE2‐specific sgRNA. ACE2 expression was analyzed by Western blotting. Black arrow indicates the band for ACE2.</p>
    </list-item>
   </list>
  </p>
  <p>
   <named-content content-type="attribution">Source data are available online for this figure.</named-content>
  </p>
 </caption>
 <graphic id="nlm-graphic-7" xlink:href="EMBJ-9999-e106057-g003" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
